

Kevin Garey

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8169093/kevin-garey-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

283
papers

10,785
citations

54
h-index

96
g-index

308
ext. papers

12,944
ext. citations

4
avg, IF

6.49
L-index

#	Paper	IF	Citations
283	Colitis caused by Clostridioides difficile infection in a domestic dog: A case report.. <i>Anaerobe</i> , 2022 , 73, 102511	2.8	
282	Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection.. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022 , 43, 28-38	3.9	0
281	Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings.. <i>Anaerobe</i> , 2022 , 102543	2.8	1
280	A Vancomycin HPLC Assay for Use in Gut Microbiome Research.. <i>Microbiology Spectrum</i> , 2022 , e01688218.9		
279	Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life.. <i>Journal of Patient-Reported Outcomes</i> , 2022 , 6, 49	2.6	1
278	157. A Multicenter, Mixed-Method Evaluation of Delayed Hospital Discharge in Patients with Invasive Candidiasis Receiving Echinocandins. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S189-S190	1	
277	1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S617-S617	1	
276	Recent developments in antimicrobial therapy for gastrointestinal infections. <i>Current Opinion in Gastroenterology</i> , 2021 , 37, 30-36	3	1
275	Impact of infection on patient-reported quality of life. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 1-6	2	3
274	Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 3303-3306	4	1
273	The metabolic profile of Bifidobacterium dentium reflects its status as a human gut commensal. <i>BMC Microbiology</i> , 2021 , 21, 154	4.5	4
272	Humoral Immune Response to Toxins A and B in Hospitalized Immunocompromised Patients With Infection. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab286	1	1
271	A multisite genomic epidemiology study of infections in the USA supports differential roles of healthcare versus community spread for two common strains. <i>Microbial Genomics</i> , 2021 , 7,	4.4	1
270	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1029-e1044	11.6	39
269	Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores. <i>Anaerobe</i> , 2021 , 69, 102352	2.8	2
268	Systemization of a pharmacy technician career ladder in a multi-hospital system.. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021 , 2, 100036		
267	Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Infection. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab365	1	5

266	Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant and. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab371	1	8
265	Knowledge and self-perception comparisons between students with and without prior technician experience in community pharmacy lab courses. <i>Currents in Pharmacy Teaching and Learning</i> , 2021 , 13, 279-287	1.5	
264	Factors associated with abnormal glucose readings in a pharmacy-led community health fair using the ADA risk assessment tool. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021 , 61, 174-180 ^{1.7}		
263	Fusobacteriumnucleatum Adheres to Clostridioides difficile via the RadD Adhesin to Enhance Biofilm Formation in Intestinal Mucus. <i>Gastroenterology</i> , 2021 , 160, 1301-1314.e8	13.3	14
262	A survey to assess experiences and social support of underrepresented minority doctor of pharmacy students. <i>Currents in Pharmacy Teaching and Learning</i> , 2021 , 13, 245-254	1.5	2
261	Antibiotic utilization within 18 community hospitals in the United States: A 5-year analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 403-408	2.6	1
260	Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. <i>Clinical Infectious Diseases</i> , 2021 , 72, e460-e465	11.6	2
259	Human-Derived Bifidobacterium dentium Modulates the Mammalian Serotonergic System and Gut-Brain Axis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 , 11, 221-248	7.9	26
258	Antibiotic Therapies for Clostridioides difficile Infection in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021 , 10, S52-S57	4.8	0
257	Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy. <i>Current HIV Research</i> , 2021 , 19, 61-72	1.3	2
256	The Integrity of Heme Is Essential for Reproducible Detection of Metronidazole-Resistant Clostridioides difficile by Agar Dilution Susceptibility Tests. <i>Journal of Clinical Microbiology</i> , 2021 , 59, e0058521	9.7	4
255	Corticosteroids Do Not Increase the Likelihood of Primary Infection in the Setting of Broad-Spectrum Antibiotic Use. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab419	1	1
254	Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. <i>Anaerobe</i> , 2021 , 70, 102387	2.8	2
253	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. <i>Clinical Infectious Diseases</i> , 2021 , 73, 755-757	11.6	15
252	Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains. <i>Anaerobe</i> , 2021 , 72, 102440	2.8	
251	Integrating gut microbiome and host immune markers to understand the pathogenesis of infection. <i>Gut Microbes</i> , 2021 , 13, 1-18	8.8	11
250	19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S13-S13	1	
249	701. An Open-label Phase 2a Study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with Clostridioides difficile Infection. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S451-S451	1	

248	18. Global Surveillance of <i>Clostridioides difficile</i> Demonstrates High Prevalence in Non-Healthcare Settings. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S12-S13	1	
247	338. Multicenter Evaluation of Superinfection Occurrence and Impact on Clinical Outcomes in Patients with COVID-19. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S273-S274	1	
246	Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	1
245	Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of () Infection. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa157	1	4
244	Activity of Omadacycline, a New Tetracycline Analog, and Comparators against <i>Clostridioides difficile</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	5
243	Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa051	1	23
242	Program development of a preceptor bootcamp for operational pharmacy preceptors. <i>American Journal of Health-System Pharmacy</i> , 2020 , 77, S2-S7	2.2	
241	Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Infection. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz552	1	12
240	PCR ribotypes of across Texas from 2011 to 2018 including emergence of ribotype 255. <i>Emerging Microbes and Infections</i> , 2020 , 9, 341-347	18.9	10
239	195. Antimicrobial Stewardship Incorporating New Antimicrobials for Use against Multi-Drug Resistant <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S102-S102 ¹		
238	798. Metronidazole Exposure Prior to <i>Clostridioides difficile</i> Infection (CDI) is a Risk Factor for Severe <i>C. difficile</i> Disease in Cancer Patients. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S442-S443	1	
237	1575. Predictors of Negative Clinical Outcomes among Patients treated with Meropenem-Vaborbactam for Serious Gram-Negative Bacterial Infections: Impact of Delayed Appropriate Antibiotic Selection. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S786-S786	1	
236	1197. Inhibitory Effect of Ursodeoxycholic Acid on <i>Clostridioides difficile</i> Growth. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S621-S621	1	
235	784. A Novel Method to Assess Virulence of <i>Clostridioides difficile</i> : Focus on <i>C. difficile</i> Ribotype 106. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S436-S437	1	
234	787. Evaluation of <i>Clostridioides difficile</i> Environmental Contamination Surrounding <i>C. difficile</i> Patients vs. non- <i>C. difficile</i> Patients in Outpatient Infusion Centers. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S438-S438	1	
233	802. Proton Pump Inhibitors Increase <i>Clostridioides difficile</i> Disease Severity Controlling for Infecting Strains. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S444-S444	1	
232	795. Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Guideline on the Classification of <i>Clostridioides difficile</i> Infection Severity. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S441-S441	1	
231	825. An Academic-Information Technology Partnership to Create an Infectious Diseases Translational Science Database. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S454-S455	1	

230	645. Absence of Toxemia in Clostridioides difficile infection: Results from Ultrasensitive Toxin Assay of Serum. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S381-S382	1	
229	43. A Pharmacoepidemiologic Evaluation of Echinocandin Use. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S45-S45	1	
228	Genomic Epidemiology of Clostridioides difficile Sequence Types 1 and 2 Across Three US Medical Centers. <i>Infection Control and Hospital Epidemiology</i> , 2020 , 41, s238-s238	2	
227	Using the Theory of Planned Behavior to Evaluate Factors That Influence PharmD Students' Intention to Attend Lectures. <i>American Journal of Pharmaceutical Education</i> , 2020 , 84, 7550	2.5	2
226	Real-world Experience of Bezlotoxumab for Prevention of Infection: A Retrospective Multicenter Cohort Study. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa097	1	13
225	Assessment of Kidney Injury as a Severity Criteria for Infection. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa476	1	4
224	Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. <i>Anaerobe</i> , 2020 , 62, 102142	2.8	7
223	Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 859-867	5.1	8
222	In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2879-2884	5.1	1
221	A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3635-3643	5.1	4
220	Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile Infection. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1140-1141	11.6	2
219	Toxin A-Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype. <i>Clinical Infectious Diseases</i> , 2020 , 70, 2628-2633	11.6	6
218	Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. <i>Anaerobe</i> , 2020 , 61, 102081	2.8	1
217	Human intestinal enteroids as a model of -induced enteritis. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 318, G870-G888	5.1	7
216	Combating resistance while maintaining innovation: the future of antimicrobial stewardship. <i>Future Microbiology</i> , 2019 , 14, 1331-1341	2.9	9
215	Molecular epidemiology of Clostridioides difficile in domestic dogs and zoo animals. <i>Anaerobe</i> , 2019 , 59, 107-111	2.8	4
214	Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways. <i>MBio</i> , 2019 , 10,	7.8	70
213	Characterization of Clostridioides difficile ribotypes in domestic dogs in Rio de Janeiro, Brazil. <i>Anaerobe</i> , 2019 , 58, 22-29	2.8	9

212	Epidemic Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz013	1	10
211	A systematic approach to optimize electronic health record medication alerts in a health system. <i>American Journal of Health-System Pharmacy</i> , 2019 , 76, 530-536	2.2	6
210	Economic health care costs of blood culture contamination: A systematic review. <i>American Journal of Infection Control</i> , 2019 , 47, 963-967	3.8	19
209	<i>Clostridioides difficile</i> ribotypes isolated from domestic environment and from patients in Bangladesh. <i>Anaerobe</i> , 2019 , 56, 88-90	2.8	5
208	Ridinilazole for the treatment of <i>Clostridioides difficile</i> infection. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 303-310	5.9	4
207	Practical Guidance for Clinical Microbiology Laboratories: A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem. <i>Clinical Microbiology Reviews</i> , 2019 , 33,	34	45
206	Complete Genome Sequence of <i>Clostridioides difficile</i> Ribotype 255 Strain Mta-79, Assembled Using Oxford Nanopore and Illumina Sequencing. <i>Microbiology Resource Announcements</i> , 2019 , 8,	1.3	3
205	RISEC: Rotational Invariant Segmentation of Elongated Cells in SEM Images with Inhomogeneous Illumination. <i>Lecture Notes in Computer Science</i> , 2019 , 553-563	0.9	
204	2248. Clinical and Microbiological Outcomes Associated with Real-World Use of Ceftolozane/Tazobactam. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S768-S769	1	1
203	2378. Corticosteroid Use Prevents Primary <i>Clostridioides difficile</i> Infection in the Setting of Broad-Spectrum Antibiotic Use Among Hospitalized Patients. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S820-S820	1	0
202	2380. Fecal <i>Collinsella</i> Abundance is Negatively Associated with Toxin A/B Production in Cancer Patients with <i>Clostridioides difficile</i> . <i>Open Forum Infectious Diseases</i> , 2019 , 6, S821-S822	1	78
201	2391. Increased Risk of Systemic Infections with Multidrug-Resistant Organisms in Patients with Severe <i>Clostridioides difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S825-S825	1	78
200	2398. Effect of Eosinopenia and Binary Toxin on <i>Clostridioides difficile</i> Infection Clinical Outcomes. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S828-S828	1	78
199	2410. Molecular Characteristics of Environmental <i>Clostridioides difficile</i> From a Large Texas Hospital. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S832-S832	1	78
198	2580. Serial Microbiome Analysis in a Patient with Multiple Failed Fecal Microbiome Transplantations. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S896-S896	1	0
197	2581. An Invertebrate Model to Study Gut Microbiome Dysbiosis. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S896-S897	1	78
196	668. Quality of Life Changes in Patients with <i>Clostridium difficile</i> Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared with Vancomycin (VAN). <i>Open Forum Infectious Diseases</i> , 2019 , 6, S306-S306	1	78
195	688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of <i>Clostridioides difficile</i> . <i>Open Forum Infectious Diseases</i> , 2019 , 6, S312-S313	1	2

194	1038. Impact of an Electronic Antibiotic Timeout on the Utilization of Frequently Prescribed Antibiotics in Hospitalized Patients. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S365-S365	1	78
193	2402. Clinical Outcomes Associated with an Emerging <i>Clostridioides difficile</i> Ribotype 255 in Texas. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S829-S829	1	78
192	840. Clinical Failure Rates Associated with Hemin-induced Metronidazole Resistance in <i>Clostridioides difficile</i> . <i>Open Forum Infectious Diseases</i> , 2019 , 6, S11-S11	1	78
191	2682. Prophylaxis-Driven Molecular Epidemiology of <i>Pseudomonas aeruginosa</i> Bloodstream Infections in Adults With Leukemia. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S942-S942	1	78
190	2235. Fecal Biomarkers for <i>Clostridioides difficile</i> Infection in Cancer Patients. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S763-S764	1	78
189	2382. Recurrent <i>Clostridioides difficile</i> Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S822-S822	1	78
188	2388. High-risk antibiotics associated with <i>Clostridioides difficile</i> infection: a national, multicenter analysis. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S825-S825	1	78
187	Activity of Hospital Disinfectants against Vegetative Cells and Spores of <i>Clostridioides difficile</i> Embedded in Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 64,	5.9	7
186	<i>Clostridioides</i> (Formerly <i>Clostridium</i>) <i>difficile</i> Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1887-1893	11.6	14
185	Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	10
184	Estimated Clinical and Economic Impact through Use of a Novel Blood Collection Device To Reduce Blood Culture Contamination in the Emergency Department: a Cost-Benefit Analysis. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	15
183	Multicentre derivation and validation of a simple predictive index for healthcare-associated <i>Clostridium difficile</i> infection. <i>Clinical Microbiology and Infection</i> , 2018 , 24, 1190-1194	9.5	10
182	Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. <i>Journal of Global Antimicrobial Resistance</i> , 2018 , 14, 58-64	3.4	45
181	Clinical Practice Guidelines for <i>Clostridium difficile</i> Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clinical Infectious Diseases</i> , 2018 , 66, e1-e48	11.6	926
180	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1678-1686	11.6	98
179	Accelerate PhenoTest BC Kit Versus Conventional Methods for Identification and Antimicrobial Susceptibility Testing of Gram-Positive Bloodstream Isolates: Potential Implications for Antimicrobial Stewardship. <i>Annals of Pharmacotherapy</i> , 2018 , 52, 754-762	2.9	9
178	Clinical Practice Guidelines for <i>Clostridium difficile</i> Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clinical Infectious Diseases</i> , 2018 , 66, 987-994	11.6	653
177	Evaluation of a shoe sole UVC device to reduce pathogen colonization on floors, surfaces and patients. <i>Journal of Hospital Infection</i> , 2018 , 98, 96-101	6.9	10

176	Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. <i>Epidemiology and Infection</i> , 2018 , 146, 1101-1105	4.3	14
175	Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals. <i>Journal of Clinical Microbiology</i> , 2018 , 56,	9.7	10
174	Bacteremia in Patients With Liver Cirrhosis: Prevalence and Predictors of Multidrug Resistant Organisms. <i>Journal of Clinical Gastroenterology</i> , 2018 , 52, 648-654	3	7
173	471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S176-S176	1	78
172	1841. Implementation of an Outpatient Antimicrobial Stewardship Program to Reduce Fluoroquinolone Overprescribing at a Veterans Affairs Medical Center (VAMC). <i>Open Forum Infectious Diseases</i> , 2018 , 5, S525-S525	1	78
171	240. Estimated Clinical and Economic Impact Through Use of an Initial Specimen Diversion Device to Reduce Blood Culture Contamination: A Cost-Benefit Analysis. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S102-S103	1	78
170	1369. Combined Analysis of the In Vitro Activity of Ridinilazole (RDZ) Against More Than 500 Clostridium difficile (CD) Clinical Isolates and Impact of RDZ on Cell Morphology. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S419-S419	1	3
169	501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S186-S186	1	78
168	510. First Environmental Investigation of Toxigenic Clostridium difficile Strains in Texas Hospitals. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S189-S189	1	78
167	Implementation and evaluation of a sterile compounding robot in a satellite oncology pharmacy. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, S51-S57	2.2	8
166	Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. <i>Infection Control and Hospital Epidemiology</i> , 2018 , 39, 1322-1329	2	10
165	Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA. <i>Journal of Global Antimicrobial Resistance</i> , 2018 , 15, 41-47	7.4	7
164	Reply to Fabre et al. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1958-1959	11.6	3
163	Association between health literacy and 30-day healthcare use after hospital discharge in the heart failure population. <i>Research in Social and Administrative Pharmacy</i> , 2017 , 13, 754-758	2.9	16
162	Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity. <i>Vaccine Journal</i> , 2017 , 24,		57
161	Effect of a Health Care System Respiratory Fluoroquinolone Restriction Program To Alter Utilization and Impact Rates of Clostridium difficile Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	29
160	Cadazolid for the treatment of Clostridium difficile. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 509-514	5.9	19
159	Mechanisms for floor surfaces or environmental ground contamination to cause human infection: a systematic review. <i>Epidemiology and Infection</i> , 2017 , 145, 347-357	4.3	16

158	First Environmental Investigation of Toxigenic Clostridium difficile at a Large Hospital in Bangladesh. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S406-S406	1	78
157	Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S52-S52	1	78
156	Investigating inpatient medication administration using the theory of planned behavior. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, 2065-2070	2.2	5
155	A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment. <i>Journal of Visualized Experiments</i> , 2017 ,	1.6	2
154	Community Environmental Contamination of Toxigenic. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx018	1	36
153	Ribotypes Matter, Significance of Clostridium difficile Ribotypes in Cancer Patients with Diarrhea. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S386-S387	1	78
152	Novel antibiotics in development to treat Clostridium difficile infection. <i>Current Opinion in Gastroenterology</i> , 2017 , 33, 1-7	3	18
151	Benchmarking and medication error rates. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 746	2.2	1
150	A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016 , 15, 22	6.2	9
149	Impact of New Diagnostic Approaches for Invasive Candidiasis on Antifungal Stewardship. <i>Current Fungal Infection Reports</i> , 2016 , 10, 68-77	1.4	1
148	Ridinilazole: a novel therapy for Clostridium difficile infection. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 137-43	14.3	32
147	Assessment of Antimicrobial Stewardship Activities in a Large Metropolitan Area. <i>Journal of Pharmacy Practice</i> , 2016 , 29, 188-93	1.3	3
146	Evaluating pharmacy leader development through the seven action logics. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 82-5	2.2	2
145	Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1245-51	5.1	38
144	Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer: A Systematic Review. <i>Nutrition in Clinical Practice</i> , 2016 , 31, 171-9	3.6	39
143	Efficacy of Bezlotoxumab in Patients Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridium difficile Infection (CDI). <i>Open Forum Infectious Diseases</i> , 2016 , 3,	1	2
142	Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, 631-7	3	27
141	Fecal Calprotectin in the Diagnosis of Clostridium difficile Infection. <i>Infectious Diseases in Clinical Practice</i> , 2016 , 24, 31-34	0.2	6

140	Epidemiology of meningitis with a negative CSF Gram stain: under-utilization of available diagnostic tests. <i>Epidemiology and Infection</i> , 2016 , 144, 189-97	4.3	26
139	Evaluating the Effects of Surotomylin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3519-23	5.9	9
138	A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile. <i>Anaerobe</i> , 2016 , 40, 10-4	2.8	4
137	Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. <i>Journal of Hospital Infection</i> , 2016 , 93, 286-9	6.9	43
136	A multi-center study of fidaxomicin use for Clostridium difficile infection. <i>SpringerPlus</i> , 2016 , 5, 1224		8
135	Shoe soles as a potential vector for pathogen transmission: a systematic review. <i>Journal of Applied Microbiology</i> , 2016 , 121, 1223-1231	4.7	16
134	Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5405-12	5.9	9
133	Age-Stratified Treatment Response Rates in Hospitalized Patients with Clostridium difficile Infection Treated with Metronidazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 6113-6	5.9	9
132	Expansion of clinical pharmacy through increased use of outpatient pharmacists for anticoagulation services. <i>American Journal of Health-System Pharmacy</i> , 2015 , 72, 568-72	2.2	5
131	Echinocandin use in hospitalized patients: a multi-institutional study. <i>American Journal of the Medical Sciences</i> , 2015 , 349, 316-20	2.2	5
130	Frequency of and risk factors for medication errors by pharmacists during order verification in a tertiary care medical center. <i>American Journal of Health-System Pharmacy</i> , 2015 , 72, 1471-4	2.2	14
129	Dispensing inhalers to patients with chronic obstructive pulmonary disease on hospital discharge: Effects on prescription filling and readmission. <i>American Journal of Health-System Pharmacy</i> , 2015 , 72, 1204-8	2.2	18
128	Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015 , 81, 4-8	2.9	29
127	Host factors and clinical outcomes of Candida colonization in critically ill patients. <i>Mycopathologia</i> , 2015 , 179, 87-93	2.9	4
126	Agreement among measurements and estimations of glomerular filtration in children with cancer. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 80-4	3	13
125	In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 1318-23	2	27
124	Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples. <i>Annals of Laboratory Medicine</i> , 2015 , 35, 306-13	3.1	14
123	Reply to Bauer and Goff. <i>Clinical Infectious Diseases</i> , 2015 , 61, 487-8	11.6	2

122	Pharmacy Practice Model Initiative task force report: Improving participation in a survey on hospital pharmacy practices in Texas. <i>American Journal of Health-System Pharmacy</i> , 2015 , 72, 1053-7	2.2	3
121	Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for <i>Clostridium difficile</i> epidemiology. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 1192-7	9.7	36
120	T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. <i>Clinical Infectious Diseases</i> , 2015 , 60, 892-9	11.6	305
119	A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe <i>Clostridium difficile</i> Infection. <i>PLoS ONE</i> , 2015 , 10, e0123405	3.7	38
118	Identification of toxemia in patients with <i>Clostridium difficile</i> infection. <i>PLoS ONE</i> , 2015 , 10, e0124235	3.7	24
117	Colonic immunopathogenesis of <i>Clostridium difficile</i> infections. <i>Vaccine Journal</i> , 2014 , 21, 509-17		22
116	Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. <i>Annals of Pharmacotherapy</i> , 2014 , 48, 683-90	2.9	33
115	Investigation of potentially pathogenic <i>Clostridium difficile</i> contamination in household environs. <i>Anaerobe</i> , 2014 , 27, 31-3	2.8	43
114	Real-time polymerase chain reaction detection of asymptomatic <i>Clostridium difficile</i> colonization and rising <i>C. difficile</i> -associated disease rates. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 667-73		86
113	1673 Microbial and Inflammatory Markers for Fatal <i>Clostridium difficile</i> Associated Diarrhea. <i>Open Forum Infectious Diseases</i> , 2014 , 1, S447-S447	1	78
112	Healthcare resource utilization for recurrent <i>Clostridium difficile</i> infection in a large university hospital in Houston, Texas. <i>PLoS ONE</i> , 2014 , 9, e102848	3.7	18
111	FKS mutant <i>Candida glabrata</i> : risk factors and outcomes in patients with candidemia. <i>Clinical Infectious Diseases</i> , 2014 , 59, 819-25	11.6	125
110	Education, training, and academic experience of newly hired, first-time pharmacy faculty members. <i>American Journal of Pharmaceutical Education</i> , 2014 , 78, 92	2.5	11
109	Immunomodulatory Agents as Adjunctive Therapy for the Treatment of Resistant <i>Candida</i> Species. <i>Current Fungal Infection Reports</i> , 2013 , 7, 119-125	1.4	2
108	Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of <i>Candida</i> species using seeded blood samples. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013 , 77, 324-6	2.9	63
107	Treatment of <i>Candida famata</i> bloodstream infections: case series and review of the literature. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 438-43	5.1	40
106	Defining acute renal dysfunction as a criterion for the severity of <i>Clostridium difficile</i> infection in patients with community-onset vs hospital-onset infection. <i>Journal of Hospital Infection</i> , 2013 , 83, 294-9	6.9	13
105	Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based <i>Clostridium difficile</i> infection treatment policy. <i>Journal of Hospital Infection</i> , 2013 , 85, 28-32	6.9	23

104	A blueprint for transitioning pharmacy residents into successful clinical faculty members in colleges and schools of pharmacy. <i>American Journal of Pharmaceutical Education</i> , 2013 , 77, 200	2.5	15
103	Impact of a pharmacotherapy alerting system on medication errors. <i>American Journal of Health-System Pharmacy</i> , 2013 , 70, 48-52	2.2	6
102	Use of rifamycin drugs and development of infection by rifamycin-resistant strains of <i>Clostridium difficile</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2690-3	5.9	28
101	Physician attitudes toward the use of fecal transplantation for recurrent <i>Clostridium difficile</i> infection in a metropolitan area. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1059-60	11.6	21
100	136. <i>Critical Care Medicine</i> , 2013 , 41, A28	1.4	
99	Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. <i>HIV/AIDS - Research and Palliative Care</i> , 2013 , 5, 153-62	1.2	8
98	Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea. <i>Drugs of Today</i> , 2013 , 49, 239-52	2.5	11
97	Overview of <i>Clostridium difficile</i> Infection as an Emerging Health Care Facility-Acquired Infection. <i>Hospital Pharmacy</i> , 2013 , 48, S1-S6	1.1	
96	Economic burden of <i>Clostridium difficile</i> infection 2013 , 60-80		1
95	Echinocandin resistance in <i>Candida</i> species: mechanisms of reduced susceptibility and therapeutic approaches. <i>Annals of Pharmacotherapy</i> , 2012 , 46, 1086-96	2.9	77
94	Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 454-9	1.6	22
93	Crofelemer for the treatment of secretory diarrhea. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012 , 6, 17-23	4.2	29
92	A real-world evaluation of oral vancomycin for severe <i>Clostridium difficile</i> infection: implications for antibiotic stewardship programs. <i>Pharmacotherapy</i> , 2012 , 32, 129-34	5.8	22
91	Pilot of a patient-centered pharmacy practice model. <i>American Journal of Health-System Pharmacy</i> , 2012 , 69, 1860-1	2.2	1
90	Evaluation of a daptomycin dose-optimization protocol. <i>American Journal of Health-System Pharmacy</i> , 2012 , 69, 979-84	2.2	7
89	Inhibition of biofilm formation by esomeprazole in <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4360-4	5.9	21
88	Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible <i>Candida</i> species in hospitalized patients with candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3239-43	5.9	38
87	Moderate to high use of opioid analgesics are associated with an increased risk of <i>Clostridium difficile</i> infection. <i>American Journal of the Medical Sciences</i> , 2012 , 343, 277-80	2.2	38

86	Bacterial colonization on writing pens touched by healthcare professionals and hospitalized patients with and without cleaning the pen with alcohol-based hand sanitizing agent. <i>Clinical Microbiology and Infection</i> , 2011 , 17, 868-9	9.5	10
85	Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after <i>Clostridium difficile</i> infection. <i>Journal of Hospital Infection</i> , 2011 , 77, 172-3	6.9	20
84	High HornQ index score predicts poor outcomes in patients with <i>Clostridium difficile</i> infection. <i>Journal of Hospital Infection</i> , 2011 , 79, 23-6	6.9	29
83	A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with <i>Clostridium difficile</i> infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2850-5	5.1	133
82	Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2146-51	5.1	62
81	Improving patient care through implementation of an antimicrobial stewardship program. <i>American Journal of Health-System Pharmacy</i> , 2011 , 68, 2170-4	2.2	16
80	Impact of multidrug-resistant <i>Pseudomonas aeruginosa</i> bacteremia on patient outcomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 3717-22	5.9	120
79	Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1160-4	5.9	104
78	Future novel therapeutic agents for <i>Clostridium difficile</i> infection. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 825-36	5.9	33
77	In vitro susceptibility of <i>Clostridium difficile</i> to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. <i>Journal of Clinical Pathology</i> , 2010 , 63, 355-8	3.9	37
76	Significant publications on infectious diseases pharmacotherapy in 2009. <i>American Journal of Health-System Pharmacy</i> , 2010 , 67, e34-42	2.2	12
75	A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent <i>Clostridium difficile</i> infection. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1406-10	11.6	52
74	Mathematical modeling to characterize the inoculum effect. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 4739-43	5.9	11
73	Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. <i>Expert Review of Anti-Infective Therapy</i> , 2010 , 8, 747-60	5.5	10
72	Crofelemer, a novel agent for treatment of secretory diarrhea. <i>Annals of Pharmacotherapy</i> , 2010 , 44, 878-84	2.9	32
71	<i>Clostridium difficile</i> infection: update on emerging antibiotic treatment options and antibiotic resistance. <i>Expert Review of Anti-Infective Therapy</i> , 2010 , 8, 555-64	5.5	86
70	Economic healthcare costs of <i>Clostridium difficile</i> infection: a systematic review. <i>Journal of Hospital Infection</i> , 2010 , 74, 309-18	6.9	228
69	Automated system to identify <i>Clostridium difficile</i> infection among hospitalised patients. <i>Journal of Hospital Infection</i> , 2009 , 72, 337-41	6.9	2

68	Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. <i>International Journal of Clinical Pharmacy</i> , 2009 , 31, 565		6
67	Clostridium difficile-related death rates in Texas 1999-2005. <i>Journal of Infection</i> , 2009 , 59, 303-7	18.9	19
66	Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009 , 63, 81-6	2.9	13
65	Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009 , 63, 279-85	2.9	15
64	Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 91-3	3	77
63	Economic benefit of appropriate timing of vancomycin prophylaxis in patients undergoing cardiovascular surgery. <i>Pharmacotherapy</i> , 2008 , 28, 699-706	5.8	7
62	A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. <i>Journal of Hospital Infection</i> , 2008 , 70, 142-7	6.9	61
61	Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. <i>Journal of Hospital Infection</i> , 2008 , 70, 298-304	6.9	287
60	Timing of fluconazole therapy and mortality in patients with Candidemia. <i>American Journal of Infection Control</i> , 2008 , 36, S174	3.8	6
59	Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. <i>Clinical Infectious Diseases</i> , 2008 , 46, 862-7	11.6	93
58	New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. <i>Current Opinion in Infectious Diseases</i> , 2008 , 21, 500-7	5.4	47
57	Killing activity of rifampin with piperacillin therapy against adherent cells of Pseudomonas aeruginosa. <i>Journal of Chemotherapy</i> , 2008 , 20, 652-4	2.3	3
56	Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. <i>Journal of Chemotherapy</i> , 2008 , 20, 714-20	2.3	38
55	Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. <i>Annals of Pharmacotherapy</i> , 2008 , 42, 827-35	2.9	51
54	Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 446-51	5.9	518
53	Significant publications on infectious diseases pharmacotherapy in 2007. <i>American Journal of Health-System Pharmacy</i> , 2008 , 65, e72-9	2.2	9
52	Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies. <i>Current Infectious Disease Reports</i> , 2008 , 10, 9-13	3.9	
51	Peripartum Clostridium difficile infection: case series and review of the literature. <i>American Journal of Obstetrics and Gynecology</i> , 2008 , 199, 332-7	6.4	32

50	New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. <i>Current Opinion in Internal Medicine</i> , 2008 , 7, 591-598		1
49	High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. <i>Current Medical Research and Opinion</i> , 2007 , 23, 1057-65	2.5	11
48	Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 964-8	6.9	40
47	Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. <i>International Journal of Antimicrobial Agents</i> , 2007 , 29, 557-62	14.3	27
46	Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 919-27	2.6	55
45	Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. <i>Clinical Microbiology and Infection</i> , 2007 , 13, 413-8	9.5	41
44	Pharmacist-managed vaccination program increased influenza vaccination rates in cardiovascular patients enrolled in a secondary prevention lipid clinic. <i>Pharmacotherapy</i> , 2007 , 27, 729-33	5.8	23
43	Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. <i>Journal of Hospital Infection</i> , 2007 , 65, 42-6	6.9	36
42	Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 35-9	5.9	133
41	Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 58, 309-14	2.9	36
40	Comparison of risk factors for candidemia versus bacteremia in hospitalized patients. <i>Infection</i> , 2006 , 34, 322-7	5.8	16
39	The importance of CD25+ CD4+ regulatory T cells in mouse hepatic allograft tolerance. <i>Liver Transplantation</i> , 2006 , 12, 1112-8	4.5	41
38	Pharmacists' Perceptions of the effectiveness of antimicrobial control programs. <i>American Journal of Health-System Pharmacy</i> , 2006 , 63, 2504-8	2.2	3
37	An integrated pharmaco-economic approach to antimicrobial formulary decision-making. <i>American Journal of Health-System Pharmacy</i> , 2006 , 63, 735-9	2.2	6
36	Prevalence of diarrhea at a university hospital and association with modifiable risk factors. <i>Annals of Pharmacotherapy</i> , 2006 , 40, 1030-4	2.9	39
35	A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1112-6	0.7	70
34	Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. <i>Annals of Pharmacotherapy</i> , 2006 , 40, 381-3	2.9	25
33	Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 645-50	5.1	90

32	Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients. <i>Journal of Chemotherapy</i> , 2006 , 18, 402-8	2.3	12
31	Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. <i>Clinical Infectious Diseases</i> , 2006 , 43, 25-31	11.6	858
30	Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. <i>Clinical Therapeutics</i> , 2006 , 28, 1208-1216	3.5	76
29	Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. <i>Mycoses</i> , 2006 , 49, 226-31	5.2	28
28	Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. <i>Expert Review of Anti-Infective Therapy</i> , 2005 , 3, 201-11	5.5	82
27	Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. <i>International Journal of Clinical Pharmacy</i> , 2005 , 27, 81-2		9
26	Economic consequences of unused medications in Houston, Texas. <i>Annals of Pharmacotherapy</i> , 2004 , 38, 1165-8	2.9	29
25	Involvement of immunization-certified pharmacists with immunization activities. <i>Annals of Pharmacotherapy</i> , 2004 , 38, 226-31	2.9	22
24	Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study. <i>Current Therapeutic Research</i> , 2004 , 65, 1-12	2.4	15
23	The Role of Matching in Epidemiologic Studies. <i>American Journal of Pharmaceutical Education</i> , 2004 , 68, 83	2.5	3
22	Markers of inflammation in exhaled breath condensate of young healthy smokers. <i>Chest</i> , 2004 , 125, 22-65.3		127
21	Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. <i>Chest</i> , 2003 , 123, 261-5	5.3	50
20	Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. <i>Investigative Ophthalmology and Visual Science</i> , 2003 , 44, 2112-7		62
19	The Role of Virus and Atypical Bacteria in the Pathogenesis of Asthma. <i>Infectious Diseases in Clinical Practice</i> , 2002 , 11, 9-15	0.2	
18	Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002 , 44, 59-61	2.9	3
17	Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. <i>Clinical Transplantation</i> , 2001 , 15, 297-308	3.8	11
16	A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. <i>Pharmacotherapy</i> , 2001 , 21, 1107-14	5.8	36
15	Telithromycin: an oral ketolide for respiratory infections. <i>Pharmacotherapy</i> , 2001 , 21, 1204-22	5.8	21

14	Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant <i>Enterococcus faecium</i> [correction of <i>faecalis</i>] ventriculitis. <i>Pharmacotherapy</i> , 2001 , 21, 748-50	5.8	17
13	<i>Cunninghamella bertholletiae</i> infection in a bone marrow transplant patient: amphotericin lung penetration, MIC determinations, and review of the literature. <i>Pharmacotherapy</i> , 2001 , 21, 855-60	5.8	28
12	<i>Chlamydia pneumoniae</i> , clarithromycin, and severe asthma. <i>Chest</i> , 2001 , 120, 1035-6	5.3	5
11	Collection and analysis of exhaled breath condensate in humans. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 164, 731-7	10.2	246
10	<i>Chlamydia pneumoniae</i> , Clarithromycin, and Severe Asthma. <i>Chest</i> , 2001 , 120, 1036	5.3	
9	Is Asthma an Infectious Disease?. <i>Clinical Pulmonary Medicine</i> , 2001 , 8, 117-122	0.3	1
8	Pharmacist intervention program for hospitalized patients with HIV infection. <i>American Journal of Health-System Pharmacy</i> , 2000 , 57, 2283-4	2.2	19
7	Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. <i>Chest</i> , 2000 , 118, 1826-7	5.3	59
6	Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclearithromycin in healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 1152-5	5.9	16
5	Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 2547-9	5.9	7
4	Trovaflaxacin: an overview. <i>Pharmacotherapy</i> , 1999 , 19, 21-34	5.8	27
3	Intravenous azithromycin. <i>Annals of Pharmacotherapy</i> , 1999 , 33, 218-28	2.9	36
2	Azathioprine hypersensitivity reaction in a patient with ulcerative colitis. <i>Annals of Pharmacotherapy</i> , 1998 , 32, 425-8	2.9	26
1	Omadacycline and <i>Clostridioides difficile</i> : A Systematic Review of Preclinical and Clinical Evidence. <i>Annals of Pharmacotherapy</i> , 106002802210890	2.9	